The Neuroendocrine Tumor (NET) Patient (pt) Perspective: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals Abstract #1217

Introduction: Despite a rising incidence of NETs, few studies document the NET pt experience. We present data on quality of life (QoL) and the global NET pt perspective.
Aim(s): To raise awareness of the NET-related burden and share pts’ perspectives on NET, medical team (MT) interactions, and educational needs.
Materials and methods: Anonymous survey of NET pts from >12 countries conducted by INCA/Novartis in 2014 (Americas, Asia, Europe, Oceania) on the NET pt experience, including disease impact, MT interactions, knowledge/awareness, and information needs. This NET patient survey was a collaboration between INCA and Novartis and the survey was funded by Novartis.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Dr John Leyden
Keywords: Quality of life

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1208 Multidisciplinary Team (MDT) in Neuroendocrine Tumor (NET) Management: Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Guidelines support an MDT approach to NETs. We present data on the global NET pt perspective regarding MDT care.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Kjell Öberg
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#1062 United Kingdom NET Patient Survey Quality of Life Results
Introduction: QoL is of paramount importance in patients diagnosed with cancer, this is especially true in patients with NETs since the median survival from diagnosis is 7 years.
Conference: 12th Annual ENETS Conference (2015)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Raj Srirajaskanthan
Keywords: Quality of life, NET
#1220 Time to Diagnosis of Neuroendocrine Tumors (NETs): Results from the First Global NET Patient (pt) Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Diagnosis of NETs often occurs late in the disease course, which may have an impact on pt survival. We present pt-reported data on time to diagnosis in global NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Marianne Pavel
Keywords: Diagnosis
#327 Long-term Results and Life Quality in Patients with Pancreatic Neuroendocrine Tumors at Munich University-Großhadern
Introduction: PNETs substantially differ from epithelial tumors in terms of tumor biology and prognosis. In specialized centers, a broad interdiscipilary armentarium can be used to achieve optimal treatment.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Sabine Zahn
Authors: Zahn S, Reincke A, Hornung H, Jauch K W, ...